What exactly changed in the QURE analyst rating on March 02, 2026?

RBC Capital downgraded uniQure (QURE) from Outperform to Sector Perform at 11:33 AM and cut its price target to $11. Cantor Fitzgerald downgraded QURE from Overweight to Neutral at 10:14 AM the same day after an FDA recommendation.

How should investors interpret the new QURE analyst rating from RBC and Cantor?

These downgrades reduce expected near-term upside and increase emphasis on regulatory risk. Investors should reassess position size, consider hedges, and await clearer FDA outcomes before adding exposure.

Did the downgrades affect QURE stock price and by how much?

Yes. The RBC-linked note tracked a **5.63%** change of **$0.56** and the Cantor note tracked a **4.53%** change of **$0.46**. The moves reflect immediate market repricing after the QURE analyst rating updates.

What does Meyka AI’s grade mean for QURE after the rating changes?

Meyka AI rates QURE **B+**. That grade blends benchmark comparisons, sector trends, growth metrics, and analyst consensus. It reflects mixed fundamentals and higher regulatory uncertainty after the recent QURE analyst rating moves.

Analyst Ratings

RBC Capital Downgrades uniQure N.V. (QURE) to Sector Perform Mar 2026

ByDanny Kontos March 3, 2026

RBC Capital downgraded uniQure N.V. (QURE) from Outperform to Sector Perform on March 02, 2026. The move is the primary QURE analyst rating update today and it came with a new price target of $11. We track a second firm, Cantor Fitzgerald, which downgraded QURE the same morning. Together these changes mark a clear shift in analyst sentiment after a recent FDA recommendation and are central to near-term trading and risk assessment for investors.